Table 2.
Follow-up |
||||
---|---|---|---|---|
Baseline Visit | Intermediate Quarter | Penultimate Quarter | Final Quarter | |
TMD incident cases (n = 211) | ||||
Adjusted PSS score, mean (SE) | 16.3 (0.5) | 16.7 (0.5) | 17.3 (0.5) | 17.7 (0.6) |
% Change relative to baseline | Referent | 2 | 6 | 9 |
P value for change | 0.319 | 0.029 | 0.003 | |
TMD-free controls (n = 173) | ||||
Adjusted PSS score, mean (SE) | 13.6 (0.5) | 14.1 (0.5) | 14.4 (0.6) | 14.0 (0.5) |
% Change relative to baseline | Referent | 4 | 6 | 3 |
P value for change | 0.181 | 0.064 | 0.458 | |
Contrast: cases versus controls | ||||
% Difference | 20 | 18 | 20 | 27 |
P value for contrast | <0.001 | <0.001 | <0.001 | <0.001 |
Adjusted means were calculated from a generalized estimating equation regression model in which the PSS score was the dependent variable; predictor variables were time of data collection (5 categories) and incident TMD case classification (2 categories) along with 2-way and 3-interactions of those predictor variables. Covariates were study site (4 categories), age (continuous measure), sex (2 categories), and race/ethnicity (5 categories). PSS scores were computed at 4 time points: the day of the baseline visit, when all subjects were TMD free; intermediate follow-up quarters were 3-mo periods after enrollment but before the penultimate quarter; the penultimate follow-up quarter was the 3-mo period preceding the final quarter; and the final follow-up quarter was the 3-mo period that coincided with the follow-up clinical visit at which incident TMD was determined. OPPERA, Orofacial Pain: Prospective Evaluation and Risk Assessment; QHU, Quarterly Health Update questionnaire; TMD, temporomandibular disorder.